National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix G: Biographical Notes on Committee Members." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
415
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

MAURICE R.HILLEMAN is director, Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories, where he also has held the positions of senior vice president and director of virus and cell biology research. From 1948 to 1958 he was chief of viral respiratory disease research at the Walter Reed Army Institute of Research; prior to that, he was chief of viral diseases at E.R.Squibb & Sons. He holds an adjunct professorship in pediatrics in the School of Medicine at the University of Pennsylvania and had prior appointments at the University of Maryland and Rutgers University. Dr. Hilleman has had a long career in academia, government, and industry and has engaged in a wide variety of basic and applied research activities in virology, immunology, epidemiology, vaccine development, and clinical evaluation. He has served as a long-term advisor to the U.S. government and the World Health Organization. He holds a Ph.D. degree from the University of Chicago in Microbiology and Virology.


GERALD T.KEUSCH has been professor of medicine and chief of the Division of Geographic Medicine, Department of Medicine, at Tufts University School of Medicine, Boston, since 1979. Prior to that, he was assistant and then associate professor of medicine at Mount Sinai School of Medicine in New York. He has been interested in the pathogenesis of diarrheal diseases and in the interaction of malnutrition and infection, and has worked in both the laboratory and the field in developing countries. He has an M.D. degree from Harvard Medical School and an A.B. from Columbia College.


RICHARD F.KINGHAM is a partner in the Washington, D.C., law firm of Covington & Burling. Since joining the firm in 1973, he has specialized in federal regulation of foods, drugs, and related products. He was involved in contract negotiations and legislative drafting in connection with the 1976 swine flu immunization program and subsequently participated in a number of proceedings relating to federal regulation of vaccines and proposals for vaccine injury compensation systems. He has served as a lecturer at the University of Virginia Law School since 1977, most recently teaching seminars in food and drug law and administrative law. He holds a J.D. degree from the University of Virginia and a B.A. degree from George Washington University.


BERNARD ROIZMAN is the Joseph Regenstein Distinguished Service Professor in the Department of Molecular Genetics and Cell Biology and chairman of the Committee on Virology at the University of Chicago, where he has been on the faculty since 1965. Prior to that he was on the faculty of Johns Hopkins University. His scientific interests center on the molecular biology of herpesviruses. He has been on the editorial board of numerous scientific journals and served as a member or chairman of advisory and review panels for the American Cancer Society, the National Science Foundation, the National Institutes of Health, the Leukemia Research Foundation, the International Committee for Taxonomy of Viruses, the International Microbial Commission, Emory University, Northwestern University, Showa University, the Sloan

Page
415
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)